Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 364

1.

Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle.

Bright RA, Carter DM, Crevar CJ, Toapanta FR, Steckbeck JD, Cole KS, Kumar NM, Pushko P, Smith G, Tumpey TM, Ross TM.

PLoS One. 2008 Jan 30;3(1):e1501. doi: 10.1371/journal.pone.0001501.

PMID:
18231588
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.

Mahmood K, Bright RA, Mytle N, Carter DM, Crevar CJ, Achenbach JE, Heaton PM, Tumpey TM, Ross TM.

Vaccine. 2008 Oct 3;26(42):5393-9. doi: 10.1016/j.vaccine.2008.07.084. Epub 2008 Aug 14.

PMID:
18706956
[PubMed - indexed for MEDLINE]
3.

Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.

Bright RA, Carter DM, Daniluk S, Toapanta FR, Ahmad A, Gavrilov V, Massare M, Pushko P, Mytle N, Rowe T, Smith G, Ross TM.

Vaccine. 2007 May 10;25(19):3871-8. Epub 2007 Feb 15.

PMID:
17337102
[PubMed - indexed for MEDLINE]
4.

H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans.

Khurana S, Wu J, Verma N, Verma S, Raghunandan R, Manischewitz J, King LR, Kpamegan E, Pincus S, Smith G, Glenn G, Golding H.

J Virol. 2011 Nov;85(21):10945-54. doi: 10.1128/JVI.05406-11. Epub 2011 Aug 24.

PMID:
21865396
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Virus-like particle vaccine comprised of the HA, NA, and M1 proteins of an avian isolated H5N1 influenza virus induces protective immunity against homologous and heterologous strains in mice.

Tao P, Luo M, Zhu D, Qu S, Yang Z, Gao M, Guo D, Pan Z.

Viral Immunol. 2009 Jul;22(4):273-81. doi: 10.1089/vim.2009.0017.

PMID:
19594398
[PubMed - indexed for MEDLINE]
6.

Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine.

Crevar CJ, Ross TM.

Virol J. 2008 Oct 28;5:131. doi: 10.1186/1743-422X-5-131.

PMID:
18957098
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines.

Giles BM, Bissel SJ, Dealmeida DR, Wiley CA, Ross TM.

Clin Vaccine Immunol. 2012 Feb;19(2):128-39. doi: 10.1128/CVI.05533-11. Epub 2011 Dec 21.

PMID:
22190399
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.

Smith GE, Flyer DC, Raghunandan R, Liu Y, Wei Z, Wu Y, Kpamegan E, Courbron D, Fries LF 3rd, Glenn GM.

Vaccine. 2013 Sep 13;31(40):4305-13. doi: 10.1016/j.vaccine.2013.07.043. Epub 2013 Jul 26.

PMID:
23891795
[PubMed - indexed for MEDLINE]
Free Article
9.

A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.

Wu CY, Yeh YC, Chan JT, Yang YC, Yang JR, Liu MT, Wu HS, Hsiao PW.

PLoS One. 2012;7(8):e42363. doi: 10.1371/journal.pone.0042363. Epub 2012 Aug 7.

PMID:
22879951
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets.

Giles BM, Ross TM.

Vaccine. 2011 Apr 5;29(16):3043-54. doi: 10.1016/j.vaccine.2011.01.100. Epub 2011 Feb 12.

PMID:
21320540
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge.

Galarza JM, Latham T, Cupo A.

Viral Immunol. 2005;18(2):365-72.

PMID:
16035948
[PubMed - indexed for MEDLINE]
12.

Gastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infection.

Prabakaran M, Madhan S, Prabhu N, Qiang J, Kwang J.

J Virol. 2010 Apr;84(7):3201-9. doi: 10.1128/JVI.02175-09. Epub 2010 Jan 13.

PMID:
20071572
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Multiple-clade H5N1 influenza split vaccine elicits broad cross protection against lethal influenza virus challenge in mice by intranasal vaccination.

Yang P, Duan Y, Zhang P, Li Z, Wang C, Dong M, Tang C, Xing L, Gu H, Zhao Z, Liu X, Zhang S, Wang X.

PLoS One. 2012;7(1):e30252. doi: 10.1371/journal.pone.0030252. Epub 2012 Jan 18.

PMID:
22279575
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Production and characterization of mammalian virus-like particles from modified vaccinia virus Ankara vectors expressing influenza H5N1 hemagglutinin and neuraminidase.

Schmeisser F, Adamo JE, Blumberg B, Friedman R, Muller J, Soto J, Weir JP.

Vaccine. 2012 May 14;30(23):3413-22. doi: 10.1016/j.vaccine.2012.03.033. Epub 2012 Mar 29.

PMID:
22465746
[PubMed - indexed for MEDLINE]
15.

Evaluation of the efficacy of a pre-pandemic H5N1 vaccine (MG1109) in mouse and ferret models.

Song MS, Moon HJ, Kwon HI, Pascua PN, Lee JH, Baek YH, Woo GJ, Choi J, Lee S, Yoo H, Oh I, Yoon Y, Rho JB, Sung MH, Hong SP, Kim CJ, Choi YK.

J Microbiol. 2012 Jun;50(3):478-88. doi: 10.1007/s12275-012-1573-z. Epub 2012 Jun 30. Erratum in: J Microbiol. 2012 Aug;50(4):715. Woo, Kyu-Jin [corrected to Woo, Gyu-Jin].

PMID:
22752912
[PubMed - indexed for MEDLINE]
16.

Co-administration of certain DNA vaccine combinations expressing different H5N1 influenza virus antigens can be beneficial or detrimental to immune protection.

Patel A, Gray M, Li Y, Kobasa D, Yao X, Kobinger GP.

Vaccine. 2012 Jan 11;30(3):626-36. doi: 10.1016/j.vaccine.2011.11.017. Epub 2011 Nov 23.

PMID:
22119588
[PubMed - indexed for MEDLINE]
17.

Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.

Prabakaran M, Velumani S, He F, Karuppannan AK, Geng GY, Yin LK, Kwang J.

Virology. 2008 Oct 25;380(2):412-20. doi: 10.1016/j.virol.2008.08.002. Epub 2008 Sep 10.

PMID:
18786689
[PubMed - indexed for MEDLINE]
Free Article
18.

Protective efficacy of baculovirus-derived influenza virus-like particles bearing H5 HA alone or in combination with M1 in chickens.

Choi JG, Kim MC, Kang HM, Kim KI, Lee KJ, Park CK, Kwon JH, Kim JH, Lee YJ.

Vet Microbiol. 2013 Mar 23;162(2-4):623-30. doi: 10.1016/j.vetmic.2012.11.035. Epub 2012 Nov 29.

PMID:
23265240
[PubMed - indexed for MEDLINE]
19.

Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection.

Mayrhofer J, Coulibaly S, Hessel A, Holzer GW, Schwendinger M, Brühl P, Gerencer M, Crowe BA, Shuo S, Hong W, Tan YJ, Dietrich B, Sabarth N, Savidis-Dacho H, Kistner O, Barrett PN, Falkner FG.

J Virol. 2009 May;83(10):5192-203. doi: 10.1128/JVI.02081-08. Epub 2009 Mar 11.

PMID:
19279103
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.

Harada Y, Ninomiya-Mori A, Takahashi Y, Shirakura M, Kishida N, Kageyama T, Tada Y, Tashiro M, Odagiri T.

Vaccine. 2011 Oct 26;29(46):8330-7. doi: 10.1016/j.vaccine.2011.08.091. Epub 2011 Sep 10.

PMID:
21911027
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk